Apex Biotechnology Corp (1733) - Total Assets

Latest as of September 2025: NT$2.31 Billion TWD ≈ $72.76 Million USD

Based on the latest financial reports, Apex Biotechnology Corp (1733) holds total assets worth NT$2.31 Billion TWD (≈ $72.76 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Apex Biotechnology Corp to assess how comfortably operating cash covers total debt obligations.

Apex Biotechnology Corp - Total Assets Trend (2002–2024)

This chart illustrates how Apex Biotechnology Corp's total assets have evolved over time, based on quarterly financial data. See Apex Biotechnology Corp (1733) net assets for net asset value and shareholders' equity analysis.

Apex Biotechnology Corp - Asset Composition Analysis

Current Asset Composition (December 2024)

Apex Biotechnology Corp's total assets of NT$2.31 Billion consist of 67.9% current assets and 32.1% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	22.0%
Accounts Receivable	NT$354.72 Million	14.7%
Inventory	NT$662.49 Million	27.4%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$39.60 Million	1.6%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2002–2024)

This chart illustrates how Apex Biotechnology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 1733 company net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Apex Biotechnology Corp's current assets represent 67.9% of total assets in 2024, an increase from 0.0% in 2002.
Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, up from 1.5% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2002.
Asset Diversification: The largest asset category is inventory at 27.4% of total assets.

Apex Biotechnology Corp Competitors by Total Assets

Key competitors of Apex Biotechnology Corp based on total assets are shown below.

Company	Country	Total Assets
Ascendis Pharma AS NASDAQ:ASND	USA	$2.01 Billion
ALTEOGEN Inc KQ:196170	Korea	₩729.47 Billion
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	USA	$1.29 Billion
Definium Therapeutics, Inc. NASDAQ:DFTX	USA	$440.10 Million
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Galapagos N.V. AS:GLPG	Netherlands	€3.37 Billion
Blue Jet Healthcare Limited NSE:BLUEJET	India	Rs16.41 Billion
Inventiva S.A PA:IVA	France	€249.51 Million

Apex Biotechnology Corp - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	4.08	3.55	1.91
Quick Ratio	2.71	2.12	1.34
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$1.18 Billion	NT$1.12 Billion	NT$801.05 Million

Apex Biotechnology Corp - Advanced Valuation Insights

This section examines the relationship between Apex Biotechnology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.63
Latest Market Cap to Assets Ratio	0.04
Asset Growth Rate (YoY)	5.4%
Total Assets	NT$2.42 Billion
Market Capitalization	$98.56 Million USD

Valuation Analysis

Below Book Valuation: The market values Apex Biotechnology Corp's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Apex Biotechnology Corp's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Apex Biotechnology Corp (2002–2024)

The table below shows the annual total assets of Apex Biotechnology Corp from 2002 to 2024.

Year	Total Assets	Change
2024-12-31	NT$2.42 Billion ≈ $76.24 Million	+5.35%
2023-12-31	NT$2.30 Billion ≈ $72.37 Million	-8.66%
2022-12-31	NT$2.51 Billion ≈ $79.23 Million	-5.83%
2021-12-31	NT$2.67 Billion ≈ $84.13 Million	+0.72%
2020-12-31	NT$2.65 Billion ≈ $83.53 Million	-5.78%
2019-12-31	NT$2.81 Billion ≈ $88.66 Million	+10.55%
2018-12-31	NT$2.55 Billion ≈ $80.20 Million	-5.71%
2017-12-31	NT$2.70 Billion ≈ $85.06 Million	+7.96%
2016-12-31	NT$2.50 Billion ≈ $78.79 Million	-7.19%
2015-12-31	NT$2.69 Billion ≈ $84.89 Million	+1.88%
2014-12-31	NT$2.64 Billion ≈ $83.33 Million	-2.90%
2013-12-31	NT$2.72 Billion ≈ $85.82 Million	-0.87%
2012-12-31	NT$2.75 Billion ≈ $86.58 Million	+28.47%
2011-12-31	NT$2.14 Billion ≈ $67.39 Million	+9.67%
2010-12-31	NT$1.95 Billion ≈ $61.45 Million	+9.91%
2009-12-31	NT$1.77 Billion ≈ $55.91 Million	+19.47%
2008-12-31	NT$1.49 Billion ≈ $46.80 Million	-4.41%
2007-12-31	NT$1.55 Billion ≈ $48.96 Million	+19.69%
2006-12-31	NT$1.30 Billion ≈ $40.90 Million	+15.89%
2005-12-31	NT$1.12 Billion ≈ $35.30 Million	+12.64%
2004-12-31	NT$994.56 Million ≈ $31.33 Million	+3.12%
2003-12-31	NT$964.43 Million ≈ $30.38 Million	+20.26%
2002-12-31	NT$801.97 Million ≈ $25.27 Million	--

About Apex Biotechnology Corp

TW:1733 Taiwan Biotechnology

Market Cap

$98.56 Million

NT$3.13 Billion TWD

Market Cap Rank

#19174 Global

#1061 in Taiwan

Share Price

NT$31.30

Change (1 day)

-1.42%

52-Week Range

NT$28.20 - NT$37.50

All Time High

NT$42.96